Summary
Small-cell lung cancer (SCLC) combined with epidermal growth factor receptor (EGFR) mutations is extremely rare, and standard chemotherapeutic strategies have not yet been established. In the present study, we report a case of a 67-year-old man who presented with combined SCLC with EGFR mutation (exon 19 deletion). Systemic chemotherapy with cisplatin and irinotecan was initiated as first-line chemotherapy, and computed tomography findings revealed tumor shrinkage after two cycles of chemotherapy. However, after the third cycle of the treatment, disease progression was observed including the appearance of pleural and pericardial effusion. Cytologic examination of pleural and pericardial effusion revealed adenocarcinoma and no characteristics of SCLC, and an EGFR mutation was detected, in line with the initial diagnosis. Afatinib was then administered as second-line chemotherapy, which resulted in a partial response that lasted for 6 months. Re-biopsy after resistance to first-line chemotherapy suggested that the adenocarcinoma component harboring the EGFR mutation became dominant in association with disease progression, and afatinib provided clinical efficacy as second-line chemotherapy.
Similar content being viewed by others
References
Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Mitsudomi T, Morita S, Yatabe Y et al (2009) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128
Fukui T, Tsuta K, Furuta K et al (2007) Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci 98:1714–1719
Tatematsu A, Shimizu J, Murakami Y et al (2008) Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 14:6092–6096
Alam N, Gustafson KS, Ladanyi M et al (2010) Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with Gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 11:E1–E4
Shiao T-H, Chang Y-L, Yu C-J et al (2011) Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol 6:195–198
van Meerbeeck JP, Fennell DA, De Ruysscher DKM (2011) Small-cell lung cancer. Lancet Oncol 378:1741–1755
S-HI O, Ziogas A, Zell JA (2008) Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43
Shigematsu H, Gazdar AF (2005) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262
Siegele BJ, Shilo K, Chao BH et al (2016) Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: two cases and a review of the literature. Lung Cancer 95:65–72
Varghese AM, Zakowski MF, Yu HA et al (2014) Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol 9(6):892
Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334
Funding
There was no funding source to acknowledge.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the declaration of Helsinki and ethical standards of the institutional and/or national research committee.
Rights and permissions
About this article
Cite this article
Tanaka, M., Ishii, H., Moribuchi, H. et al. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation. Invest New Drugs 36, 715–717 (2018). https://doi.org/10.1007/s10637-018-0586-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-018-0586-9